Overall Survival as a Primary End Point in Multiple Myeloma Trials

While progression-free survival may be a reasonable endpoint for first-line multiple myeloma trials given the disease’s long median survival, there are important scenarios—such as trials in penta-refractory patients with short life expectancies or those testing maintenance therapies that add toxicity—where overall survival and quality of life should remain the primary endpoints.